Journal ArticleDOI
Idarubicin and cyclophosphamide--an active oral chemotherapy regimen for advanced breast cancer
Reads0
Chats0
TLDR
The combination chemotherapy is active in heavily treated patients with manageable toxicity but there are problems in heavily pre-treated patients.Abstract:
Between October 1993 and September 1994, 33 women with metastatic breast cancer aged between 29 and 74 years with a median age of 58 were entered into a study of oral chemotherapy from three UK centres. Patients by definition had metastatic disease and were fit and well with performance status 0 or 1 in 23 cases, 2 in seven cases and 3 in two cases (one missing). Five patients had received prior adjuvant CMF chemotherapy, nine first line non-anthracycline containing chemotherapy for relapse, eight patients second line non-anthracycline containing chemotherapy and all patients had had hormone therapy either as adjuvant or for relapsed disease. Adjuvant radiotherapy had been given to 17 and palliative radiotherapy to 12 patients. In nine patients there was one site of disease at start of therapy, in 10 two sites, in 11 three sites and in three patients four or more sites. The regimen comprised oral idarubicin 15 mg/m 2 on day 1, 10 mg/m 2 on days 2 and 3 and oral cyclophosphamide 250 mg/m 2 (maximum 400 mg) on days 1, 2 and 3. Treatment was continued until disease progression or toxicity. Results : Overall 25% of 32 evaluable patients responded objectively including one complete response; 50% of patients had stable disease and 25% of patients progression. Among patients who had had no prior chemotherapy the objective response rate was 37.5%; 45% of patients had symptomatic improvement. The most common severe toxicity was granulocytopenia WHO grade 3 or more in 69.7% of patients. Thrombocytopenia grade 3 or 4 was seen in four patients. Six patients had documented infections and all but four patients had alopecia. All patients complained of mild or moderate fatigue. Nausea and vomiting occurred in 75% of patients but only four individuals had grade 3 toxicity. Two patients stopped therapy after myocardial infarction and one after impaired cardiac function was noted. The median time to progression was 2.7 months (1–11.5 months) and median survival time 8.8 months (1–13+ months). Conclusion : The combination chemotherapy is active in heavily treated patients with manageable toxicity but there are problems in heavily pre-treated patients. There was good compliance in taking medication and at the doses chosen the drugs appear to be suitable for younger fitter patients.read more
Citations
More filters
Journal ArticleDOI
CNS Metastases in Breast Cancer
TL;DR: On the basis of data from randomized trials and retrospective series, neurosurgery and stereotactic radiosurgery (SRS) may prolong survival in patients with single brain metastases.
Journal ArticleDOI
Effective oral chemotherapy for breast cancer: pillars of strength
TL;DR: The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in Breast cancer management in the future in both the metastatic and adjuvant settings.
Journal ArticleDOI
Inhibiting eukaryotic ribosome biogenesis.
Dominik Awad,Dominik Awad,Michael Prattes,Lisa Kofler,Ingrid Rössler,Mathias Loibl,Melanie Pertl,Gertrude Zisser,Heimo Wolinski,Brigitte Pertschy,Helmut Bergler +10 more
TL;DR: The results provide for the first time a comprehensive set of inhibitors to study ribosome biogenesis by chemical inhibition of individual maturation steps and establish the process as promising druggable pathway for chemical intervention.
Journal ArticleDOI
Acceptance of oral chemotherapy in breast cancer patients - a survey study
Sarah Schott,Andreas Schneeweiss,J. Reinhardt,Thomas Bruckner,Christoph Domschke,Christof Sohn,Michael Eichbaum +6 more
TL;DR: P.o. chemotherapy shows a high acceptance in MBC patients under palliative therapy, and compliance can be achieved in particular through a differentiated indication, patient education and competent support along a p. o. or i.v. treatment.
Journal ArticleDOI
Structural investigation of idarubicin-DNA interaction: spectroscopic and molecular docking study.
Sonika Charak,Ranjana Mehrotra +1 more
TL;DR: Structural and conformational studies associated with binding of IDR on DNA double helix were investigated through spectroscopic techniques and molecular docking studies, showing that IDR is a moderate binder.
References
More filters
Journal ArticleDOI
Patient preferences for oral versus intravenous palliative chemotherapy.
TL;DR: Patients with incurable cancer have a clear preference for oral CT, but are generally not willing to sacrifice efficacy for their preference.
Journal ArticleDOI
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
Ph. Rougier,Antoine Adenis,Michel Ducreux,M. de Forni,J. Bonneterre,M. Dembak,P. Clouet,A. Lebecq,P. Baille,F. Lefresne-Soulas,C. Blanc,J.P. Armand +11 more
TL;DR: The aim of this study was to evaluate the efficacy of docetaxel as first-line chemotherapy in patients with unresectable metastatic metastatic or locally advanced pancreatic adenocarcinoma and to further characterise the safety and pharmacokinetic profiles of docentaxel.
Journal ArticleDOI
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
TL;DR: Mitoxantrone is an effective and better tolerated alternative to the anthracyclines in most haematological malignancies, in breast cancer and in advanced hepatic or ovarian carcinoma, and synergy with other antineoplastic drugs has been demonstrated in murine tumour models.
Journal Article
Idarubicin: a brief overview on pharmacology and clinical use.
TL;DR: IDA has become an important drug in the treatment of acute leukemias and its potency in lymphomas, plasmocytomas and other solid tumors such as breast cancer is currently under investigation in several clinical studies.
Journal ArticleDOI
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer.
Massimo Lopez,A. Contegiacomo,Patrizia Vici,Concetta Dello Ioio,Luigi Di Lauro,C. Pagliarulo,Silvia Carpano,Diana Giannarelli,Sabino De Placido,Serafino Fazio,A. Raffaele Bianco +10 more
TL;DR: The results of this study indicate that, although DX remains the best single agent available in the treatment of breast cancer, IDA may have a role in selected patients with this disease.